Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Albuminuria | 4 | 2010 | 681 | 0.590 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 3511 | 0.340 |
Why?
|
| Proteinuria | 1 | 2010 | 658 | 0.290 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 664 | 0.280 |
Why?
|
| Hypertension | 4 | 2010 | 8479 | 0.240 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2010 | 2038 | 0.230 |
Why?
|
| Quinazolines | 1 | 2010 | 1356 | 0.220 |
Why?
|
| Nitric Oxide | 1 | 2010 | 2132 | 0.200 |
Why?
|
| Carcinoma | 1 | 2010 | 2375 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 3143 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 257 | 0.120 |
Why?
|
| Hemofiltration | 1 | 2015 | 57 | 0.120 |
Why?
|
| Erythema Multiforme | 1 | 2004 | 31 | 0.120 |
Why?
|
| Acid-Base Equilibrium | 1 | 2015 | 185 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 4262 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2015 | 313 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 745 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 5535 | 0.110 |
Why?
|
| Exercise | 1 | 2010 | 5615 | 0.110 |
Why?
|
| Acyclovir | 1 | 2004 | 272 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 4839 | 0.110 |
Why?
|
| Valine | 1 | 2004 | 413 | 0.100 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2010 | 19 | 0.100 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2010 | 83 | 0.100 |
Why?
|
| Natriuresis | 1 | 2010 | 124 | 0.100 |
Why?
|
| Postmenopause | 1 | 2009 | 2460 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2010 | 13695 | 0.090 |
Why?
|
| Cyclic GMP | 1 | 2010 | 409 | 0.090 |
Why?
|
| Creatine | 1 | 2010 | 421 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2010 | 601 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2010 | 23406 | 0.070 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1472 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2017 | 2265 | 0.070 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 758 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 1968 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 2569 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3508 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2010 | 25041 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2010 | 3914 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 2455 | 0.050 |
Why?
|
| Muramoylpentapeptide Carboxypeptidase | 1 | 2000 | 26 | 0.050 |
Why?
|
| Hexosyltransferases | 1 | 2000 | 53 | 0.050 |
Why?
|
| Peptidyl Transferases | 1 | 2000 | 54 | 0.050 |
Why?
|
| Motor Activity | 1 | 2010 | 2715 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 3799 | 0.040 |
Why?
|
| Middle Aged | 7 | 2017 | 213388 | 0.040 |
Why?
|
| Age Factors | 2 | 2010 | 18373 | 0.040 |
Why?
|
| Bacillus subtilis | 1 | 2000 | 359 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 15535 | 0.040 |
Why?
|
| Algorithms | 1 | 2017 | 13882 | 0.030 |
Why?
|
| Risk Factors | 3 | 2010 | 72295 | 0.030 |
Why?
|
| Female | 8 | 2017 | 380200 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2010 | 8551 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.030 |
Why?
|
| Creatinine | 1 | 2008 | 1919 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 40558 | 0.030 |
Why?
|
| Adult | 5 | 2015 | 214056 | 0.030 |
Why?
|
| Humans | 9 | 2017 | 744376 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 9240 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 4982 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1462 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2004 | 470 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 2015 | 1150 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2556 | 0.020 |
Why?
|
| Aged | 4 | 2017 | 163284 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 6459 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 23336 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 40077 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 1203 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 1956 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2000 | 5023 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 3854 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2759 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2017 | 3680 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 63115 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2017 | 5316 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 21693 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2004 | 2987 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2017 | 53291 | 0.010 |
Why?
|
| Male | 3 | 2017 | 350118 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 21747 | 0.010 |
Why?
|
| Lac Operon | 1 | 2000 | 238 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 20950 | 0.010 |
Why?
|
| Spores, Bacterial | 1 | 2000 | 118 | 0.010 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2000 | 137 | 0.010 |
Why?
|
| Sigma Factor | 1 | 2000 | 175 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 12961 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 168770 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2000 | 2255 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2000 | 655 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2000 | 1122 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 4569 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3773 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 12797 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 5868 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 13814 | 0.000 |
Why?
|
| Escherichia coli | 1 | 2000 | 4217 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 18111 | 0.000 |
Why?
|
| Mutation | 1 | 2000 | 29786 | 0.000 |
Why?
|
Concepts
(99)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_